Identifying risk factors of immune reconstitution inflammatory syndrome in AIDS patients receiving highly active anti-retroviral therapy

AUTOR(ES)

He, Bo, Zheng, Yuhuang, Liu, Meng, Zhou, Guoqiang, Chen, Xia, Mamadou, Diallo, He, Yan, Zhou, Huaying, Chen, Zi

FONTE

Braz J Infect Dis

DATA DE PUBLICAÇÃO

2013-04

RESUMO

Immune reconstitution inflammation syndrome typically occurs within days after patients undergo highly active anti-retroviral therapy and is a big hurdle for effective treatment of AIDS patients. In this study, we monitored immune reconstitution inflammation syndrome occurrence in 238 AIDS patients treated with highly active anti-retroviral therapy. Among them, immune reconstitution inflammation syndrome occurred in 47 cases (19.7%). Immune reconstitution inflammation syndrome patients had significantly higher rate of opportunistic infection (p < 0.001) and persistently lower CD4+ cell count (p < 0.001) compared to the non-immune reconstitution inflammation syndrome patients. In contrast, no significant differences in HIV RNA loads were observed between the immune reconstitution inflammation syndrome group and non-immune reconstitution inflammation syndrome group. These data suggest that a history of opportunistic infection and CD4+ cell counts at baseline may function as risk factors for immune reconstitution inflammation syndrome occurrence in AIDS patients as well as potential prognostic markers. These findings will improve the management of AIDS with highly active anti-retroviral therapy.

Documentos Relacionados

• Parasitoses intestinais em portadores de HIV/AIDS nas eras prà e pÃs terapia anti-retroviral potente
• Dyslipidemia in AIDS patients on highly active antiretroviral therapy
• Immune reconstitution in HIV-1 infected patients treated for two years with highly active antiretroviral therapy
• Incidence and risk factors of immune reconstitution inflammatory syndrome in HIV-TB coinfected patients
• Assessment of cytokine values in serum by RT-PCR in HIV-1 infected individuals with and without highly active anti-retroviral therapy (HAART)